Osvaldo D Castelán-Martínez1, Ricardo Jiménez-Méndez2, Felipe Rodríguez-Islas3, María Fierro-Evans4, Benjamín E Vázquez-Gómez5, Aurora Medina-Sansón6, Patricia Clark7, Bruce Carleton2, Colin Ross2, Claudette Hildebrand2, Gilberto Castañeda-Hernández8, Rodolfo Rivas-Ruiz9. 1. Departamento de Farmacología, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico; Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, Dr. Márquez No. 162, Col. Doctores Del. Cuauhtémoc, Mexico City 06720, Mexico. 2. Pharmaceutical Outcomes and Policy Innovation Program, Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, Canada. 3. Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, Dr. Márquez No. 162, Col. Doctores Del. Cuauhtémoc, Mexico City 06720, Mexico. 4. Departamento de Audiología y Foniatría, Hospital Infantil de México Federico Gómez, Mexico City, Mexico. 5. Departamento de Neurofisiología, Hospital de Pediatría IMSS, Mexico City, Mexico. 6. Departamento de Hemato-Oncología, Hospital Infantil de México Federico Gómez, Mexico City, Mexico. 7. Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, Dr. Márquez No. 162, Col. Doctores Del. Cuauhtémoc, Mexico City 06720, Mexico; Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. 8. Departamento de Farmacología, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico. 9. Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, Dr. Márquez No. 162, Col. Doctores Del. Cuauhtémoc, Mexico City 06720, Mexico; Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: rivasrodolfo@gmail.com.
Abstract
OBJECTIVE: Cisplatin is widely used to treat a variety of pediatric solid tumors. One of the most severe and debilitating adverse drug reactions experienced by patients who receive cisplatin therapy is permanent bilateral hearing loss. The aim of this study was to evaluate the incidence and risk factors for cisplatin-induced hearing loss in Mexican pediatric patients. METHODS: Detailed medical and drug histories, including use of cisplatin as well as other drugs known to cause hearing loss, were collected from patient medical records. Results of audiology tests on pediatric patients with solid tumors were collected at baseline, during treatment and at the end of cisplatin chemotherapy. Hearing loss was classified according to the Common Terminology Criteria for Adverse Events. Bivariate and multivariate analyses were performed using survival curves. RESULTS: Fifty-nine pediatric patients, median age 11 years (range, 3-17 years) were included in the study. The incidence of cisplatin-induced hearing loss was 56%. Individual risk factors including age (< 5 years), male sex, and concomitant medications were not associated with an increased risk of cisplatin-induced hearing loss. Patients with a diagnosis of osteosarcoma and a cumulative cisplatin dose greater than 400 mg/m(2) were at higher risk of hearing loss compared with all other tumor and cumulative dose combinations (HR = 2.47 [95% CI, 1.043-5.831]). CONCLUSIONS: Cumulative dose and tumor type are associated with an increased risk of cisplatin-induced hearing loss. Further research is required to characterize fully the interindividual variation in hearing loss in Mexican patients.
OBJECTIVE:Cisplatin is widely used to treat a variety of pediatric solid tumors. One of the most severe and debilitating adverse drug reactions experienced by patients who receive cisplatin therapy is permanent bilateral hearing loss. The aim of this study was to evaluate the incidence and risk factors for cisplatin-induced hearing loss in Mexican pediatric patients. METHODS: Detailed medical and drug histories, including use of cisplatin as well as other drugs known to cause hearing loss, were collected from patient medical records. Results of audiology tests on pediatric patients with solid tumors were collected at baseline, during treatment and at the end of cisplatin chemotherapy. Hearing loss was classified according to the Common Terminology Criteria for Adverse Events. Bivariate and multivariate analyses were performed using survival curves. RESULTS: Fifty-nine pediatric patients, median age 11 years (range, 3-17 years) were included in the study. The incidence of cisplatin-induced hearing loss was 56%. Individual risk factors including age (< 5 years), male sex, and concomitant medications were not associated with an increased risk of cisplatin-induced hearing loss. Patients with a diagnosis of osteosarcoma and a cumulative cisplatin dose greater than 400 mg/m(2) were at higher risk of hearing loss compared with all other tumor and cumulative dose combinations (HR = 2.47 [95% CI, 1.043-5.831]). CONCLUSIONS: Cumulative dose and tumor type are associated with an increased risk of cisplatin-induced hearing loss. Further research is required to characterize fully the interindividual variation in hearing loss in Mexican patients.
Authors: Annette Weiss; Grit Sommer; Rahel Kuonen; Katrin Scheinemann; Michael Grotzer; Martin Kompis; Claudia E Kuehni Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Lauren K Dillard; Lucero Lopez-Perez; Ricardo X Martinez; Amanda M Fullerton; Shelly Chadha; Catherine M McMahon Journal: Cancer Epidemiol Date: 2022-06-17 Impact factor: 2.890
Authors: Olga Morales-Ríos; Carlo Cicero-Oneto; Carlos García-Ruiz; Dina Villanueva-García; Maribelle Hernández-Hernández; Víctor Olivar-López; Rodolfo Norberto Jiménez-Juárez; Luis Jasso-Gutiérrez Journal: PLoS One Date: 2020-03-24 Impact factor: 3.240